Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2011-06-14
2011-06-14
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C530S351000, C435S069510, C435S419000, C536S023520
Reexamination Certificate
active
07959910
ABSTRACT:
The present invention provides biologically active variants of human α-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human α-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human α-2b-interferon. The invention encompasses these biologically active variant α-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant α-interferon polypeptides and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4956282 (1990-09-01), Goodman et al.
patent: 5256410 (1993-10-01), Tanner et al.
patent: 5550038 (1996-08-01), Goodman et al.
patent: 5629175 (1997-05-01), Goodman et al.
patent: 5780709 (1998-07-01), Adams et al.
patent: 6040498 (2000-03-01), Stomp et al.
patent: 6096546 (2000-08-01), Raskin
patent: 6096547 (2000-08-01), Goodman et al.
patent: 6288302 (2001-09-01), Yu et al.
patent: 6610830 (2003-08-01), Goeddel et al.
patent: 6774283 (2004-08-01), Goodman et al.
patent: 6815184 (2004-11-01), Stomp et al.
patent: 7161064 (2007-01-01), Stomp et al.
patent: 2003/0115640 (2003-06-01), Stomp et al.
patent: 2003/0135887 (2003-07-01), Brandle et al.
patent: 2003/0167531 (2003-09-01), Russell et al.
patent: 2004/0073968 (2004-04-01), Stomp et al.
patent: 2004/0219131 (2004-11-01), Patten et al.
patent: 2005/0060776 (2005-03-01), Stomp et al.
patent: 2005/0221344 (2005-10-01), Welcher et al.
patent: 2006/0024272 (2006-02-01), Reinl et al.
patent: 2006/0195946 (2006-08-01), Dickey et al.
patent: 2007/0044177 (2007-02-01), Stomp et al.
patent: 2009/0025106 (2009-01-01), Reinl et al.
patent: 2009/0282584 (2009-11-01), Stomp et al.
patent: 393690 (1991-11-01), None
patent: 0032134 (1981-07-01), None
patent: 0141484 (1985-05-01), None
patent: 0 194 006 (1986-09-01), None
patent: 0 256 424 (1988-02-01), None
patent: WO 99/07210 (1999-02-01), None
patent: WO 01/36001 (2001-05-01), None
patent: WO 02/10414 (2002-02-01), None
patent: WO 02/43650 (2002-06-01), None
patent: WO 03/002152 (2003-01-01), None
patent: WO 2004/046365 (2004-06-01), None
Ackerman, S.K., et al., Biologic Activity in a Fragment of Recombinant Human Interferon α,Proc. Natl. Acad. Sci., USA, 1984, pp. 1045-1047, vol. 81.
Arnheiter, H., et al., “Orientation of a Human Leukocyte Interferon Molecule on its Cell Surface Receptor: Carboxyl Terminus Remains Accessible to a Monoclonal Antibody Made Against a Synthetic Interferon Fragment,”Proc. Natl. Acad. Sci., USA, 1983, pp. 2539-2543, vol. 80.
Chang, N.T., et al., “Synthesis of a Human Leukocyte Interferon with a Modified Carboxy Terminus inEscherichia coli,” Archives of Biochemistry and Biophysics, 1983, pp. 585-589, vol. 221(2).
Cheetham, B.F., et al., “Structure-Function Studies of Human Interferons-α Enhanced Activity on Human and Murine Cells,”Antiviral Research, 1991, pp. 27-40, vol. 15.
Franke, A.E., et al., “Carboxyterminal Region of Hybrid Leukocyte Interferons Affects Antiviral Specificity,”DNA, 1982, vol. 1(3).
Gasdaska, J.R., et al., Advantages of Therapeutic Protein Production in the Aquatic PlantLemna, www.bioprocessingjoumal.com, Mar./Apr. 2003.
Levy, W.P., et al., “Amino Acid Sequence of a Human Leukocyte Interferon,”Proc. Natl. Acad. Sci, USA, 1981, pp. 6186-6190, vol. 78(10).
Chang, et al., “Evolution of a cytokine using DNA family shuffling”,Nature Biotech. (1999) 17:793-797.
Döbeli, H. et al., “Role of the carboxyl-terminal sequence on the biological activity of human immune interferon (IFN-Gamma),”Journal of Biotechnology, 1988, vol. 7(3), pp. 199-216.
Horisberger, M. et al., “Interferon-Alpha Hybrids,”Pharmacology&Therapeutics, 1995, vol. 66(3), pp. 507-534.
Houghton, “Human Interferon Gene Sequences,”Nature, 1980, vol. 285(5766), pp. 536.
Mantei, et al., “The nucleotide sequence of a cloned human leukocyte interferon cDNA”,Gene(1980) 10:1-10.
Mantei, et al., “The nucleotide sequence of a cloned human leukocyte interferon cDNA”,Chemical Abstracts(1980) 93:489, Abstract No. 130319s.
Nacheva, G. et al., “Human interferon gamma: significance of the C-terminal flexible domain for its biological activity,”Archives of Biochemistry and Biophysics, 2003, vol. 413(1), pp. 91-981.
Nagata, et al., “The structure of one of the eight or more distinct chromosomal genes for human intereferon-alpha”,Nature(1980) 287(5781):401-408.
Nagata, et al., “Synthesis inE. coliof a polypeptide with human leukocyte interferon activity”,Chemical Abstracts(1980) 93:479, Abstract No. 41286m.
Nagata, et al., “Synthesis inE. coliof a polypeptide with human leukocyte interferon activity”,Nature(1980) 284:316-320.
Ozes, et al., “A comparison of Interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities”,J. Interferon Res. (1992) 12:55-59.
Pestka and Langer, “Interferons and their actions”,Ann. Rev. Biochem. (1987) 56:727-77.
Platis and Foster, “High yield expression, refolding, and characterization of recombinant interferon α2/α8 hybrids inEscherichia coli”, Protein Expression and Purfication(2003) 31:222-230.
Rubinstein, et al., “Human leukocyte interferon: isolation and characterization of several molecular forms”,Arch. of Biochem. and Biophysics(1981) 210:307-318.
Rubinstein, et al., “Human leukocyte interferon purified to homogeneity”,Science(1978) 202(4374):1289-1290.
Rubinstein, et al., “Human leukocyte interferon: production, purification to homogeneity, and initial characterization”,Proc. Natl. Acad. Sci. USA(1979) 76(2):640-644.
Schilliberg, et al., “Review—Molecular Farming of Recombinant Antibodies in Plants,” (2003)CMLA, Cell. Mol. Life Sci. 60:433-445.
Streuli, et al., “At least three human type alpha interferons: structure of alpha 2”,Science(1980) 209(4463):1343-1347.
Sugyiama, et al., “Expression of Human Interferon-a2 in Sf9 Cells,”Dur. J. Biochem. (1993) 271:921-927.
Taniguchi, et al., “Expression of the Human Fibroblast Interferon Gene inEscherichia coli”, Proc. Natl. Acad. Sci. USA(1980) 77(9):5230-5233.
Taniguchi, et al., “Human leukocyte and fibroblast interferons are structurally related”,Nature(1980) 285:547-549.
Torma and Paucker, “Purification and characterization of human leukocyte interferon components”,J. Biol. Chem. (1976) 251(16):4810-4816.
Weissmann, “The cloning of interferon and other mistakes”,Interferon(1981) 3:101-134.
Zoon, et al., “Amino terminal sequence of the major component of human lymphoblastoid interferon”,Science(1980) 207(4430):527-528.
Zoon, et al., “Purification and partial characterization of human lymphoblastoid interferon”,Proc. Natl. Acad. Sci. USA(1979) 76(11):5601-5605.
Zoon, et al., “Human lymphoblastoid interferon: purification, amino acid composition, and amino-terminal sequence”,Ann. NY Acad. Sci. (1980) 350:390-398.
Zhu, et al., “Expression of Human a-Interferon cDNA in Transgenic Rice Plants,”Plant Cell, Tissue and Organ Culture(1994) 36:197-204.
Cox Kevin
Dickey Lynn
Gasdaska John
Alston & Bird LLP
Biolex Therapeutics, Inc.
Hissong Bruce D
Landsman Robert
LandOfFree
C-terminally truncated interferon alpha variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-terminally truncated interferon alpha variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-terminally truncated interferon alpha variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2623961